Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic
Ephrin receptor A2 (EphA2) is a member of the Ephrin/Eph receptor cell-to-cell signaling household of molecules, and it performs a key function in cell proliferation, differentiation, and migration. EphA2 is overexpressed in a broad vary of cancers, and its expression is in lots of instances related to poor prognosis.
We not too long ago developed a novel EphA2-targeting antibody-directed nanotherapeutic encapsulating a labile prodrug of docetaxel for the therapy of EphA2-expressing malignancies. Right here, we characterised the expression of EphA2 in bladder most cancers utilizing immunohistochemistry in 177 human bladder most cancers samples and decided the preclinical efficacy of EphA2-ILs-DTXp in 4 EphA2-positive patient-derived xenograft (PDX) fashions of the illness, both as a monotherapy, or together with gemcitabine.
EphA2 expression was detected in 80-100% of bladder most cancers samples and correlated with shorter affected person survival. EphA2 was discovered to be expressed in tumor cells and/or tumor-associated blood vessels in each main and metastatic lesions with a concordance charge of roughly 90%.
The EphA2-targeted antibody-directed nanotherapeutic EphA2-ILs-DTXp managed tumor development, mediated larger regression, and was extra lively than free docetaxel at equitoxic dosing in all 4 EphA2-positive bladder most cancers PDX fashions. Mixture of EphA2-ILs-DTXp and gemcitabine in a single PDX mannequin led to improved tumor development management in comparison with monotherapies or the mixture of free docetaxel and gemcitabine.
These information demonstrating the prevalence of EphA2 in bladder cancers and efficacy of EphA2-ILs-DTXp in PDX fashions help the medical exploration of EphA2 focusing on in bladder most cancers.
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic

Novel anti-EPHA2 antibody, DS-8895a for most cancers therapy.

Overexpression of EPHA2 has been noticed in a number of cancers and reported to be related to poor prognosis. Right here, we produced an afucosylated humanized anti-EPHA2 monoclonal antibody (mAb), DS-8895a for most cancers therapy. The antibody acknowledges the extracellular juxtamembrane area of EPHA2 and subsequently can bind to each full-length and truncated types of EPHA2, that are anchored to cell membranes and not too long ago reported to be produced by post-translational cleavage in tumors.
DS-8895a exhibited markedly elevated antibody dependent mobile cytotoxicity (ADCC) in vitro and in addition inhibited tumor development in EPHA2-positive human breast most cancers MDA-MB-231 and human gastric most cancers SNU-16 xenograft mouse fashions.
Furthermore, DS-8895a together with cisplatin (CDDP) confirmed higher efficacy than every of the monotherapies did within the human gastric most cancers mannequin. These outcomes counsel {that a} novel antibody, DS-8895a has therapeutic potential towards EPHA2-expressing tumors.
EphA2 is a receptor tyrosine kinase that has been proven to be overexpressed in quite a lot of human tumor sorts. Earlier research demonstrated that agonist monoclonal antibodies focusing on EphA2 induced the internalization and degradation of the receptor, thereby abolishing its oncogenic results.
On this examine, the in vitro and in vivo antibody-dependent cell-mediated cytotoxicity (ADCC) exercise of EphA2 effector-enhanced agonist monoclonal antibodies was evaluated. With tumor cell traces and wholesome human peripheral blood monocytes, the EphA2 antibodies demonstrated roughly 80% tumor cell killing. In a dose-dependent method, pure killer (NK) cells had been required for the in vitro ADCC exercise and have become activated as demonstrated by the induction of cell floor expression of CD107a.

EPHA2 antibody

10R-2017 100 ul
EUR 403
Description: Mouse monoclonal EPHA2 antibody

EphA2 antibody

10R-1108 100 ul
EUR 316
Description: Mouse monoclonal EphA2 antibody

EPHA2 Antibody

43267-100ul 100ul
EUR 252

EPHA2 Antibody

DF4778 200ul
EUR 304
Description: EPHA2 Antibody detects endogenous levels of total EPHA2.

EPHA2 Antibody

CSB-PA282887-
EUR 335
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

EPHA2 Antibody

CSB-PA282887-100ul 100ul
EUR 316
  • Form: liquid
  • Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
  • Show more
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000

EPHA2 Antibody

1-CSB-PA179150
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

EPHA2 antibody

70R-49696 100 ul
EUR 456
Description: Purified Polyclonal EPHA2 antibody

EPHA2 Antibody

AF5238 200ul
EUR 304
Description: EPHA2 Antibody detects endogenous levels of total EPHA2.

EphA2 Antibody

BF0613 200ul
EUR 376
Description: EphA2 antibody detects endogenous levels of total EphA2.

EPHA2 Antibody

1-CSB-PA007722GA01HU
  • EUR 597.00
  • EUR 333.00
  • 150ul
  • 50ul
  • Form: Liquid
  • Buffer: PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20℃, Avoid freeze / thaw cycles. Antigen Affinity Purified
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC

EPHA2 Antibody

1-CSB-PA007722LA01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200

EPHA2 Antibody

1-CSB-PA007983
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against EPHA2. Recognizes EPHA2 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/40000
To evaluate the function of NK cells on antitumor efficacy in vivo, the EphA2 antibodies had been evaluated in xenograft fashions in extreme compromised immunodeficient (SCID) mice (which have purposeful NK cells and monocytes) and SCID nonobese diabetic (NOD) mice (which largely lack purposeful NK cells and monocytes).

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

The importance of morphological identification of African anopheline mosquitoes (Diptera: Culicidae) for malaria control programmes.

The importance of morphological identification of African anopheline mosquitoes (Diptera: Culicidae) for malaria control programmes.The importance of morphological identification of African anopheline mosquitoes (Diptera: Culicidae) for malaria control programmes.

The proper identification of illness vectors is step one in direction of implementing an efficient management programme. Historically, for malaria management, this was primarily based on the morphological variations noticed